Dupixent Approved in Canada for Atopic Dermatitis in Children
Health Canada has given Sanofi’s biologic Dupixent (dupilumab injection) approval for treating atopic dermatitis in children.
Specifically, the agency approved the drug for treating moderate-to-severe atopic dermatitis in children ages six to 11 who do not see adequate control with topical prescription therapies or cannot take them. The monoclonal antibody works by inhibiting the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins.
The company said that the biologic’s new indication is the first granted for treating atopic dermatitis in patients aged six to 11.